Junzo Hamanishi

Kyoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 170 publications

Correction: Differentiating uterine adenosarcoma from endometrial polyps: MRI imaging features.

Correction: Differentiating uterine adenosarcoma from endometrial polyps: MRI imaging features.

Journal: Abdominal radiology (New York)

Published: June 01, 2026

AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study.

AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study.

Journal: Cancer science

Published: December 23, 2025

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.

Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.

Journal: Cancer science

Published: December 10, 2025

Title: AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 study.

Title: AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 study.

Journal: Cancer immunology, immunotherapy : CII

Published: December 08, 2025

Lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer: a retrospective multi-institutional survey in the Kinki district of Japan.

Lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer: a retrospective multi-institutional survey in the Kinki district of Japan.

Journal: Cancer treatment and research communications

Published: November 21, 2025

Clinical Significance and Therapeutic Applications of Tertiary Lymphoid Structures(TLS)in Gynecological Cancers

Clinical Significance and Therapeutic Applications of Tertiary Lymphoid Structures(TLS)in Gynecological Cancers

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: October 06, 2025

Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models.

Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models.

Journal: Cancer immunology, immunotherapy : CII

Published: September 28, 2025

Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial.

Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial.

Journal: Cancer immunology, immunotherapy : CII

Published: August 30, 2025

A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma.

A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma.

Journal: Molecular cancer therapeutics

Published: August 14, 2025

Healthcare provider bias in cancer treatment decisions for elderly patients.

Healthcare provider bias in cancer treatment decisions for elderly patients.

Journal: Taiwanese journal of obstetrics & gynecology

Published: July 11, 2025

HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.

HIF2A as a prognostic and clinical therapeutic target in ovarian clear cell carcinoma.

Journal: International journal of cancer

Published: July 02, 2025

Adjuvant Chemotherapy in Stage I Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-analysis.

Adjuvant Chemotherapy in Stage I Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-analysis.

Journal: Obstetrics and gynecology

Published: June 12, 2025

Showing 1-12 of 170

Last Updated: 09/26/2026